The NSF "Systemic" Projects- A New Tradition

Nephrogenic Systemic Fibrosis (NSF)

When first described in 2000, NSF was noted to occur predominantly in patients with end-stage chronic kidney disease (CKD), particularly in patients on dialysis. In 2006 several groups noted a strong association between gadolinium-based contrast agent (GBCA) administration in patients with advanced renal disease and the development of NSF [1,2], and it is now generally accepted that GBCA exposu...

Toward a Theory of Systemic Reform: The Case of Nine NSF Statewide Systemic Initiatives

Nephrogenic systemic fibrosis (NSF): the role of tamoxifen

Dear Sir, Nephrogenic systemic fibrosis (NSF) is exclusively found in patients with marked renal impairment who have been exposed to gadolinium (Gd) through its use as a contrast agent in magnetic resonance imaging (MRI) studies [1]. The main clinical feature of NSF is thickening and hardening of the skin, and joint contractures are common. There is no confirmed effective treatment for NSF and ...

A new editorial phase with new projects.

Correspondence: Revista Española de Cardiología. Sociedad Española de Cardiología. Nuestra Señora de Guadalupe, 5-7. 28028 Madrid. Spain. E-mail: [email protected] Revista Española de Cardiología (REC) renewed its editorial team last October during the Spanish Congress on Cardiovascular Diseases held in Barcelona, after the previous team had completed the 6-year term stipulated in the statu...

Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents

Until recently it was believed that extracellular gadolinium based contrast agents were safe for both the kidneys and all other organs within the dose range up to 0.3 mmol/kg body weight. However, in 2006, it was demonstrated that some gadolinium based contrast agents may trigger the development of nephrogenic systemic fibrosis, a generalised fibrotic disorder, in renal failure patients. Accord...